

6237.NCP DV1


Amend to 08/25/2004 Office Communication

-1-PA

Specification

Please replace the paragraph of formula I on page 3, line 17 to page 5, line 24 with the following paragraph:

- 5 A compound of formula I:

**I**

where a is a single bond or double bond, and where

R1a, R1b, R2a and R2b are each independently

10

(a) H, Cl, Br, I, F, CN, CF₃, OCF₃, OR₅, CONR₅R₆, COR₅, CO[[2]]₂R₅, Y(CH₂)_mXR₅ or YC(O)(CH₂)_mXR₅, where m = 0-3, Y = CH₂, S, O, or NR₆, X = CH₂, S, O, NR₆;

- 15 (b) (CH[[2]]₂)_pAr where p = 0-3 and Ar is aryl or heteroaryl optionally substituted with one or more of the following: H, halogen, CN, NO₂, OR₇, CF₃, OCF₃, SR₇, SO₂R₇, SO₂NR₇R₈, NR₇R₈, CONR₇R₈, NR₇COR₈, NR₇CONR₈R₉, CO₂R₇, COR₇, or R₇; or

- 20 (c) linear or branched C₁-C₈ alkyl, linear or branched C₂-C₈ alkenyl, linear or branched C₂-C₈ alkynyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkenyl, or C₃-C₈ cycloalkynyl; wherein any of these groups may be optionally substituted with one or more of the following: halogen, CN, NO₂, COR₇, OR₇, NR₇R₈, SR₇, CO[[2]]₂R₇, CONR₇R₈ or NR₇COR₈; and where

25

R₃ is

(a) H, Cl, Br, I, F, CN, CF₃, OCF₃, alkyl, Ar, OR₅, SR₅, CHO, CONR₅R₆, COR₅, CO[[2]]₂R₅, (Y)_o(CH[[2]]₂)_nXR₅, C(O)C(O)XR₅, (Y)_o(CH₂)_nC(O)XR₅,

BEST AVAILABLE COPY

6237.NCP DV1

Amend to 08/25/2004 Office Communication

-2-PA

(Y)_o(CH₂)_nN(R6)C(O)OR5, (Y)_o(CH₂)_nN(R6)C(O)NR5R6 where o = 0 or 1, n = 0-3, X = CH₂, S, O, or NR6 and Y = CH₂, S, O or NR6, where Ar is aryl or heteroaryl optionally substituted with one or more of the following: H, halogen, CN, NO₂, OR7, CF₃, OCF₃, SR7, SO₂R7, SO₂NR7R8, NR7R8, CONR7R8, NR7COR8, NR7CONR8R9, CO₂R7, COR7, or R7; or

(b) linear or branched C₁-C₈ alkyl, linear or branched C₂-C₈ alkenyl, linear or branched C₂-C₈ alkynyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkenyl, or C₃-C₈ cycloalkynyl; wherein any of these groups may be optionally substituted with one or more of the following: halogen, CN, NO₂, COR10, OR10, NR10R8, SR10, CO₂R10, CONR10R8 or NR10COR8; and where

R4, R5 and R6 are each independently

(a) H, linear or branched C₁-C₈ alkyl, linear or branched C₂-C₈ alkenyl, linear or branched C₂-C₈ alkynyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkenyl, or C₃-C₈ cycloalkynyl; wherein any of these groups other than H may be optionally substituted with one or more of the following: halogen, CN, NO₂, COR10, OR10, NR10R11, SR10, CO₂R10, CONR10R11 or NR10COR11; or where R5 and R6 are linked to form a 3 to 8 member ring; or

(b) (CH₂)_pAr where p = 0-3 and Ar is aryl or heteroaryl optionally substituted with one or more of the following: H, halogen, CN, NO₂, OR7, CF₃, OCF₃, SR7, SO₂R7, SO₂NR7R8, NR7R8, CONR7R8, NR7COR8, NR7CONR8R9, CO₂R7, COR7, or R7; and where

R7, R8, and R9 are each independently

(a) H, linear or branched C₁-C₈ alkyl, linear or branched C₂-C₈ alkenyl, linear or branched C₂-C₈ alkynyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkenyl, or C₃-C₈ cycloalkynyl groups, wherein any of these groups other than H may be optionally substituted with halogen, CN, NO₂, COR10, OR10, NR10R11, SR10, CO₂R10, CONR10R11, NR10COR11, NR10CONR11R12, or where R7, R8, or R9 are linked to form a ring;

OR

6237.NCP DV1
Amend to 08/25/2004 Office Communication
-3-PA

- (b) $(\text{CH}[[2]]_2)_p\text{Ar}$ where $p = 0-3$ and Ar is aryl or heteroaryl optionally substituted with one or more of the following: H, halogen, CN, NO_2 , OR10, CF_3 , OCF_3 , SR10, SO_2R_{10} , $\text{SO}_2\text{NR}_{10}\text{R}_{11}$, $\text{NR}_{10}\text{R}_{11}$, $\text{CONR}_{10}\text{R}_{11}$, $\text{NR}_{10}\text{COR}_{11}$, $\text{NR}_{10}\text{CONR}_{11}\text{R}_{12}$,
5 CO_2R_{10} , COR10, or R10; and where

- R10, R11 and R12 are each independently H, linear or branched $\text{C}_1\text{-C}_8$ alkyl, linear or branched $\text{C}_2\text{-C}_8$ alkenyl, linear or branched $\text{C}_2\text{-C}_8$ alkynyl, $\text{C}_3\text{-C}_8$ cycloalkyl, $\text{C}_3\text{-C}_8$ cycloalkenyl, or $\text{C}_3\text{-C}_8$ cycloalkynyl;
10
or a stereoisomer or pharmaceutically acceptable salt thereof.


6237.NCP DV1

Amend to 08/25/2004 Office Communication

-4-PA

Please replace the paragraph of formula I on page 9, line 1 to page 11, line 27 with the following paragraph:

A compound of formula I:



I

5

where a is a single bond or double bond, and where

R1a, R1b, R2a and R2b are each independently

- 10 (a) H, Cl, Br, I, F, CN, CF₃, OCF₃, OR₅, CONR₅R₆, COR₅, CO[[2]]₂R₅, Y(CH₂)_mXR₅ or YC(O)(CH₂)_mXR₅, where m = 0-3, Y = CH₂, S, O, or NR₆, X = CH₂, S, O, NR₆;
- (b) (CH[[2]]₂)_pAr where p = 0-3 and Ar is aryl or heteroaryl optionally substituted
- 15 with one or more of the following: H, halogen, CN, NO₂, OR₇, CF₃, OCF₃, SR₇, SO₂R₇, SO₂NR₇R₈, NR₇R₈, CONR₇R₈, NR₇COR₈, NR₇CONR₈R₉, CO₂R₇, COR₇, or R₇; or
- (c) linear or branched C₁-C₈ alkyl, linear or branched C₂-C₈ alkenyl, linear or
- 20 branched C₂-C₈ alkynyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkenyl, or C₃-C₈ cycloalkynyl; wherein any of these groups may be optionally substituted with one or more of the following: halogen, CN, NO₂, COR₇, OR₇, NR₇R₈, SR₇, CO[[2]]₂R₇, CONR₇R₈ or NR₇COR₈; and where
- 25 R₃ is
- (a) H, Cl, Br, I, F, CN, CF₃, OCF₃, alkyl, Ar, OR₅, SR₅, CHO, CONR₅R₆, COR₅, CO[[2]]₂R₅, (Y)_o(CH[[2]]₂)_nXR₅, C(O)C(O)XR₅, (Y)_o(CH₂)_nC(O)XR₅, C(O)(CH[[2]]₂)_nXR₅, (Y)_o(CH[[2]]₂)_nN(R₆)C(O)R₅, (Y)_o(CH[[2]]₂)_nN(R₆)S(O)₂R₅,

30

(Y)_o(CH[[2]]₂)_nN(R₆)C(O)OR₅, (Y)_o(CH[[2]]₂)_nN(R₆)C(O)NR₅R₆ where o = 0 or 1

6237.NCP DV1

Amend to 08/25/2004 Office Communication

-5-PA

n = 0-3, X = CH₂, S, O, or NR₆ and Y=CH₂, S, O or NR₆, where Ar is aryl or heteroaryl optionally substituted with one or more of the following: H, halogen, CN, NO₂, OR₇, CF₃, OCF₃, SR₇, SO₂R₇, SO₂NR₇R₈, NR₇R₈, CONR₇R₈, NR₇COR₈, NR₇CONR₈R₉, CO₂R₇, COR₇, or R₇; or

5

(b) linear or branched C₁-C₈ alkyl, linear or branched C₂-C₈ alkenyl, linear or branched C₂-C₈ alkynyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkenyl, or C₃-C₈ cycloalkynyl; wherein any of these groups may be optionally substituted with one or more of the following: halogen, CN, NO₂, COR₁₀, OR₁₀, NR₁₀R₈, SR₁₀, CO[[2]]₂R₁₀,

10 CONR₁₀R₈ or NR₁₀COR₈; and where

R₄, R₅ and R₆ are each independently

(a) H, linear or branched C₁-C₈ alkyl, linear or branched C₂-C₈ alkenyl, linear or branched C₂-C₈ alkynyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkenyl, or C₃-C₈ cycloalkynyl; wherein any of these groups other than H may be optionally substituted with one or more of the following: halogen, CN, NO₂, COR₁₀, OR₁₀, NR₁₀R₁₁, SR₁₀, CO[[2]]₂R₁₀, CONR₁₀R₁₁ or NR₁₀COR₁₁; or where R₅ and R₆ are linked to form a 3 to 8 member ring; or

20

(b) (CH₂)_pAr where p = 0-3 and Ar is aryl or heteroaryl optionally substituted with one or more of the following: H, halogen, CN, NO₂, OR₇, CF₃, OCF₃, SR₇, SO₂R₇, SO₂NR₇R₈, NR₇R₈, CONR₇R₈, NR₇COR₈, NR₇CONR₈R₉, CO₂R₇, COR₇, or R₇; and where

25

R₇, R₈, and R₉ are each independently

(a) H, linear or branched C₁-C₈ alkyl, linear or branched C₂-C₈ alkenyl, linear or branched C₂-C₈ alkynyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkenyl, or C₃-C₈ cycloalkynyl groups, wherein any of these groups other than H may be optionally substituted with halogen, CN, NO₂, COR₁₀, OR₁₀, NR₁₀R₁₁, SR₁₀, CO[[2]]₂R₁₀, CONR₁₀R₁₁, NR₁₀COR₁₁, NR₁₀CONR₁₁R₁₂, or where R₇, R₈, or R₉ are linked to form a ring; or

30

6237.NCP DV1

Amend to 08/25/2004 Office Communication

-6-PA

(b) $(\text{CH}[[2]]_2)_p\text{Ar}$ where $p = 0-3$ and Ar is aryl or heteroaryl optionally substituted with one or more of the following: H, halogen, CN, NO_2 , OR10, CF_3 , OCF_3 , SR10, SO_2R_{10} , $\text{SO}_2\text{NR}_{10}\text{R}_{11}$, $\text{NR}_{10}\text{R}_{11}$, $\text{CONR}_{10}\text{R}_{11}$, $\text{NR}_{10}\text{COR}_{11}$, $\text{NR}_{10}\text{CONR}_{11}\text{R}_{12}$, CO_2R_{10} , COR10, or R10; and where

5

R10, R11 and R12 are each independently H, linear or branched $\text{C}_1\text{-C}_8$ alkyl, linear or branched $\text{C}_2\text{-C}_8$ alkenyl, linear or branched $\text{C}_2\text{-C}_8$ alkynyl, $\text{C}_3\text{-C}_8$ cycloalkyl, $\text{C}_3\text{-C}_8$ cycloalkenyl, or $\text{C}_3\text{-C}_8$ cycloalkynyl;

10 or a stereoisomer or pharmaceutically acceptable salt thereof.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.